BIOTALYS NV (BTLS.BR) Fundamental Analysis & Valuation

EBR:BTLS • BE0974386188

Current stock price

2.12 EUR
-0.2 (-8.62%)
Last:

This BTLS.BR fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. BTLS.BR Profitability Analysis

1.1 Basic Checks

  • In the past year BTLS has reported negative net income.
  • In the past year BTLS has reported a negative cash flow from operations.
  • In the past 5 years BTLS always reported negative net income.
  • In the past 5 years BTLS always reported negative operating cash flow.
BTLS.BR Yearly Net Income VS EBIT VS OCF VS FCFBTLS.BR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -5M -10M -15M -20M

1.2 Ratios

  • BTLS has a Return On Assets of -51.18%. This is amonst the worse of the industry: BTLS underperforms 94.29% of its industry peers.
  • With a Return On Equity value of -74.88%, BTLS is not doing good in the industry: 90.00% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -51.18%
ROE -74.88%
ROIC N/A
ROA(3y)-45.95%
ROA(5y)-38.32%
ROE(3y)-62.54%
ROE(5y)-51.65%
ROIC(3y)N/A
ROIC(5y)N/A
BTLS.BR Yearly ROA, ROE, ROICBTLS.BR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for BTLS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BTLS.BR Yearly Profit, Operating, Gross MarginsBTLS.BR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024

6

2. BTLS.BR Health Analysis

2.1 Basic Checks

  • The number of shares outstanding for BTLS has been increased compared to 1 year ago.
  • BTLS has more shares outstanding than it did 5 years ago.
  • The debt/assets ratio for BTLS has been reduced compared to a year ago.
BTLS.BR Yearly Shares OutstandingBTLS.BR Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 10M 20M 30M
BTLS.BR Yearly Total Debt VS Total AssetsBTLS.BR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 20M 40M 60M

2.2 Solvency

  • BTLS has an Altman-Z score of 3.84. This indicates that BTLS is financially healthy and has little risk of bankruptcy at the moment.
  • BTLS has a Altman-Z score of 3.84. This is amongst the best in the industry. BTLS outperforms 81.43% of its industry peers.
  • BTLS has a Debt/Equity ratio of 0.16. This is a healthy value indicating a solid balance between debt and equity.
  • BTLS's Debt to Equity ratio of 0.16 is fine compared to the rest of the industry. BTLS outperforms 70.00% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.16
Debt/FCF N/A
Altman-Z 3.84
ROIC/WACCN/A
WACCN/A
BTLS.BR Yearly LT Debt VS Equity VS FCFBTLS.BR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 20M -20M 40M

2.3 Liquidity

  • BTLS has a Current Ratio of 3.61. This indicates that BTLS is financially healthy and has no problem in meeting its short term obligations.
  • With an excellent Current ratio value of 3.61, BTLS belongs to the best of the industry, outperforming 92.86% of the companies in the same industry.
  • A Quick Ratio of 3.61 indicates that BTLS has no problem at all paying its short term obligations.
  • BTLS has a Quick ratio of 3.61. This is amongst the best in the industry. BTLS outperforms 95.71% of its industry peers.
Industry RankSector Rank
Current Ratio 3.61
Quick Ratio 3.61
BTLS.BR Yearly Current Assets VS Current LiabilitesBTLS.BR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

2

3. BTLS.BR Growth Analysis

3.1 Past

  • BTLS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 19.48%, which is quite good.
EPS 1Y (TTM)19.48%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-7.58%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • BTLS is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 5.80% yearly.
  • BTLS is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 10.43% yearly.
EPS Next Y1.76%
EPS Next 2Y21.76%
EPS Next 3Y5.8%
EPS Next 5YN/A
Revenue Next Year-52%
Revenue Next 2Y3.92%
Revenue Next 3Y10.43%
Revenue Next 5YN/A

3.3 Evolution

BTLS.BR Yearly Revenue VS EstimatesBTLS.BR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2023 2024 2025 2026 2027 2M 4M 6M
BTLS.BR Yearly EPS VS EstimatesBTLS.BR Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 -0.1 -0.2 -0.3 -0.4

0

4. BTLS.BR Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for BTLS. In the last year negative earnings were reported.
  • Also next year BTLS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BTLS.BR Price Earnings VS Forward Price EarningsBTLS.BR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BTLS.BR Per share dataBTLS.BR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4 -0.4

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y21.76%
EPS Next 3Y5.8%

0

5. BTLS.BR Dividend Analysis

5.1 Amount

  • No dividends for BTLS!.
Industry RankSector Rank
Dividend Yield 0%

BTLS.BR Fundamentals: All Metrics, Ratios and Statistics

BIOTALYS NV

EBR:BTLS (3/18/2026, 7:00:00 PM)

2.12

-0.2 (-8.62%)

Chartmill FA Rating
GICS SectorMaterials
GICS IndustryGroupMaterials
GICS IndustryChemicals
Earnings (Last)09-18
Earnings (Next)03-27
Inst Owners21.54%
Inst Owner ChangeN/A
Ins Owners4.83%
Ins Owner ChangeN/A
Market Cap79.65M
Revenue(TTM)N/A
Net Income(TTM)-14.83M
Analysts84.44
Price Target7.21 (240.09%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-10.17%
PT rev (3m)-10.55%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 4.02
P/tB 4.14
EV/EBITDA N/A
EPS(TTM)-0.41
EYN/A
EPS(NY)-0.2
Fwd EYN/A
FCF(TTM)-0.33
FCFYN/A
OCF(TTM)-0.33
OCFYN/A
SpS0
BVpS0.53
TBVpS0.51
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -51.18%
ROE -74.88%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-45.95%
ROA(5y)-38.32%
ROE(3y)-62.54%
ROE(5y)-51.65%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.16
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 5.8%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.61
Quick Ratio 3.61
Altman-Z 3.84
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)25.97%
Cap/Depr(5y)109.26%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)19.48%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-7.58%
EPS Next Y1.76%
EPS Next 2Y21.76%
EPS Next 3Y5.8%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year-52%
Revenue Next 2Y3.92%
Revenue Next 3Y10.43%
Revenue Next 5YN/A
EBIT growth 1Y9.21%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-5.38%
EBIT Next 3Y2.83%
EBIT Next 5YN/A
FCF growth 1Y37.31%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y35.88%
OCF growth 3YN/A
OCF growth 5YN/A

BIOTALYS NV / BTLS.BR Fundamental Analysis FAQ

What is the ChartMill fundamental rating of BIOTALYS NV (BTLS.BR) stock?

ChartMill assigns a fundamental rating of 2 / 10 to BTLS.BR.


Can you provide the valuation status for BIOTALYS NV?

ChartMill assigns a valuation rating of 0 / 10 to BIOTALYS NV (BTLS.BR). This can be considered as Overvalued.


How profitable is BIOTALYS NV (BTLS.BR) stock?

BIOTALYS NV (BTLS.BR) has a profitability rating of 0 / 10.


How financially healthy is BIOTALYS NV?

The financial health rating of BIOTALYS NV (BTLS.BR) is 6 / 10.